NasdaqGM - Delayed Quote USD

PureTech Health plc (PRTC)

Compare
19.94 +0.04 (+0.20%)
At close: October 18 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Bharatt M. Chowrira J.D., Ph.D. CEO & Executive Director 2.19M -- 1965
Ms. Daphne Zohar Founder, Senior Advisor & Board Observer 3.99M -- 1971
Dr. Robert S. Langer Jr., Ph.D., ScD Co-Founder & Non-Executive Director 135k -- 1949
Dr. Eric Elenko Ph.D. Co-Founder & President -- -- 1973
Dr. David R. Elmaleh Ph.D. Co-Founder & Senior Advisor -- -- 1948
Mr. Michael Inbar CPA, M.B.A. Senior Vice President of Finance -- -- --
Mr. Eric Green M.B.A. Chief Operating Officer -- -- --
Ms. Allison Mead Talbot Head of Communications & Investor Relations -- -- --
Mr. Charles Sherwood III, J.D., Ph.D. General Counsel & Company Secretary -- -- --
Mr. Spencer Ball Senior Vice President of Human Resources -- -- --

PureTech Health plc

6 Tide Street
Suite 400
Boston, MA 02210
United States
617 482 2333 https://www.puretechhealth.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
90

Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Corporate Governance

PureTech Health plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 28, 2024 at 12:30 PM UTC

PureTech Health plc Earnings Date

Recent Events

September 27, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

August 28, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

August 22, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

July 9, 2024 at 12:00 AM UTC

SC 13D/A: Tender Offer/Acquisition Reports

June 24, 2024 at 12:00 AM UTC

SC TO-I/A: Tender Offer/Acquisition Reports

June 20, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

June 13, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

June 6, 2024 at 12:00 AM UTC

SC TO-I/A: Tender Offer/Acquisition Reports

June 4, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

May 30, 2024 at 12:00 AM UTC

SC 13D/A: Tender Offer/Acquisition Reports

Related Tickers